NCT03588923View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 7, 2018

Primary Completion Date

August 10, 2018

Study Completion Date

August 10, 2018

Conditions
HCV Infection
Interventions
DRUG

SH229

tablet, oral, 400 mg once daily for 3 days

DRUG

Placebos

tablet, oral, once daily for 3 days

DRUG

SH229

tablet, oral, 600 mg once daily for 3 days

DRUG

Placebos

tablet, oral, once daily for 3 days

DRUG

SH229

tablet, oral, 800 mg once daily for 3 days

DRUG

Placebos

tablet, oral, once daily for 3 days

Trial Locations (1)

130000

Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

Nanjing Sanhome Pharmaceutical, Co., Ltd.

INDUSTRY

NCT03588923 - Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection | Biotech Hunter | Biotech Hunter